Skip to content

Cognitive Impairment Cohort Study of the Elderly Population in SheMountain

Shanghai Cognitive Impairment Study of the Elderly Population: SheMountain Cohort

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05667935
Acronym
SheMountain
Enrollment
2000
Registered
2022-12-29
Start date
2022-12-26
Completion date
2031-01-31
Last updated
2022-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Cognitive Impairment, Dementia, Mild Cognitive Impairment, Neurodegenerative Diseases

Keywords

Alzheimer disease, Mild cognitive impairment, cohort, Disease Progression

Brief summary

This study is a prospective observational study, which involves a cohort of 2000 all-sex and all-ethnic people aged 60 years and above with permanent residence in Tianma area, SheMountain Town, Songjiang District (suburban area), Shanghai. Demographic information, neuropsychiatric scale, peripheral blood, APOE genotype, brain MRI, speech information, AV45-PET, FDG-PET, Tau-PET, GLP-1R PET, and cholinergic receptor probe (ASEM) PET were collected and analyzed. Follow-up visits were performed twice a year for 4 visits, and neuropsychiatric scales and biological samples were collected at each follow-up visit to construct a diagnostic model for patients with mild cognitive impairment, or Alzheimer's disease, as well as a predictive model for the progression of cognitive impairment.

Detailed description

This study is a prospective observational study, which involves a cohort of 2000 all-sex and all-ethnic people aged 60 years and above with permanent residence in Tianma area, SheMountain Town, Songjiang District (suburban area), Shanghai. Demographic information, neuropsychiatric scale, peripheral blood serum Aβ40, Aβ42, p-tau 181, 217, urine proteomic analysis, APOE genotype analysis, brain MRI, and speech information were collected and analyzed. After initial screening 20% of patients with clinically confirmed MCI and AD were randomly selected for AV45-PET, FDG-PET, Tau-PET, GLP-1R PET, and cholinergic receptor probe (ASEM) PET. Follow-up visits were performed twice a year for 4 visits, and neuropsychiatric scales and biological samples were collected at each follow-up visit to construct a diagnostic model for patients with mild cognitive impairment, or Alzheimer's disease, as well as a predictive model for the progression of cognitive impairment.

Interventions

None listed

Sponsors

Ruijin Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. All genders and all ethnic groups aged 60 and above with permanent residence in Tianma area, SheMountain Town, Songjiang District (suburbs), Shanghai. 2. Agree to collect neuropsychiatric scales, biological samples, imaging and other examination information. 3. Agree to participate in this study and sign the informed consent form. And promise to abide by the research procedures, and cooperate with the implementation of the whole process of research

Exclusion criteria

1. Suffering from severe mental illness, tumor cachexia, severe liver and kidney dysfunction and other serious physical diseases and unable to cooperate 2. Uncorrectable visual or auditory impairment that hampers the completion of related examination.

Design outcomes

Primary

MeasureTime frameDescription
The change of incidence of cognitive impairmentbaseline, 2 year, 4 year, 6 year, 8 yearNumber of participants who covert to AD or mild cognitive impairment (MCI) will be recorded to calculate the incidence.

Secondary

MeasureTime frameDescription
The change of Montreal cognitive assessment-Basic (MoCA)baseline, 2 year, 4 year, 6 year, 8 yearMoCA is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity.
The change of Auditory verbal learning test (AVLT)baseline, 2 year, 4 year, 6 year, 8 yearAVLT is a screening instrument used to assess the function of memory. The score in long-term memory (N5) ranges from 0 to 12, with lower scores indicating greater disease severity.
The change of Geriatric Depression Scale (GDS)baseline, 2 year, 4 year, 6 year, 8 yearGDS is a neuropsychological scale used to assess the level of depression. The total score ranges from 0 to 30, with higher scores indicating greater disease severity.
The change of 36-Item Short Form Survey (SF-36)baseline, 2 year, 4 year, 6 year, 8 yearThe Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. And it consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.
The change of Mini-Mental State Examination (MMSE)baseline, 2 year, 4 year, 6 year, 8 yearMMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity.
Positron emission tomography (PET)-CTbaselineIncluding AV45-PET, FDG-PET, Tau-PET, GLP-1R PET, Cholinergic receptor probe (ASEM) PET will be used to detect the amyloid, Tau burden and AD related GLP-1R as well as Cholinergic receptor change.
The change of blood concentration of Phosphorylated Tau, Concentration of Amyloid β (Aβ)baseline, 2 year, 4 year, 6 year, 8 yearBlood serum p-tau 181, p-tau 217, Aβ40 and Aβ42at baseline will be tested. The higher blood p-tau is a strong predictor for AD.
The change of Activities of daily living (ADL)baseline, 2 year, 4 year, 6 year, 8 yearADL is a scale used in healthcare to refer to people's daily self-care activities. Eight factors are rated to produce an overall score on a point scale of 0 to 100. The lower the score the more independence in living.
The change of speech informationbaseline, 2 year, 4 year, 6 year, 8 yearVoice data collection, use a voice recorder to collect the patient's description of stealing biscuit map language, and save it in SWV format. And use self-developed ASR speech analysis software (China software copyright number: 2016RS164680) for speech analysis.
The change of MRI neuroimagingbaseline, 2 year, 4 year, 6 year, 8 yearEvaluation of brain MRI by high-resolution structural T1 imaging, diffusion tensor imaging, and blood oxygenation level dependent (BOLD) imaging.

Countries

China

Contacts

Primary ContactGang Wang, MD, PhD
wg11424@rjh.com.cn086-021-64370045

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026